Adenylosuccinate lyase deficiency
ah-deh-nil-oh-suk-sin-ate ly-ase deficiency
Also known as: ASLD, Adenylosuccinase deficiency
At a Glance
What is Adenylosuccinate lyase deficiency?
Adenylosuccinate lyase deficiency is a rare genetic disorder that primarily affects the brain and muscles. It is caused by mutations in the ADSL gene, leading to a deficiency in the enzyme adenylosuccinate lyase. This enzyme is crucial for the production of purines, which are necessary for DNA and RNA synthesis. Over time, the lack of this enzyme causes a buildup of toxic substances in the body, leading to neurological symptoms. Early symptoms may include developmental delay, seizures, and muscle weakness. As the condition progresses, individuals may experience intellectual disability and behavioral issues. Early diagnosis is critical to manage symptoms and improve quality of life. The disorder can have a significant impact on family life, requiring ongoing medical care and support. Prognosis varies, but many individuals face lifelong challenges. Daily life for affected individuals often involves managing symptoms and attending various therapies. Supportive care and interventions can help improve outcomes and quality of life.
Medical Definition
Adenylosuccinate lyase deficiency is a metabolic disorder characterized by the accumulation of succinylpurines due to mutations in the ADSL gene. Pathologically, it involves the disruption of purine nucleotide cycle, leading to neurological and muscular symptoms. Histologically, there may be evidence of neuronal damage and muscle atrophy. It is classified under inborn errors of metabolism and is inherited in an autosomal recessive manner. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course is progressive, with symptoms typically appearing in infancy and worsening over time.
Adenylosuccinate lyase deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Developmental delay manifests as a significant lag in achieving motor, cognitive, and social milestones compared to peers. This is caused by impaired purine metabolism leading to inadequate energy supply in neurons. Over time, the delay can become more pronounced, potentially resulting in lifelong disabilities. It affects daily life by limiting independence and learning abilities, but early intervention with therapies can help improve skills.
Seizures present as sudden, uncontrolled electrical disturbances in the brain, causing changes in behavior, movements, or consciousness. They occur due to the accumulation of toxic metabolites that disrupt normal neuronal function. Without management, seizures can increase in frequency and severity, impacting brain development. Daily life is affected by the need for constant supervision and medication, but antiepileptic drugs can help control seizures.
Hypotonia, or decreased muscle tone, results in floppy muscles and poor head control. It is caused by disruptions in neuromuscular signaling due to metabolic imbalances. Over time, hypotonia can lead to joint instability and delayed motor skills. It affects daily activities like sitting and walking, but physical therapy can improve muscle strength and coordination.
Common
Autism spectrum disorder manifests as challenges in social interaction, communication, and repetitive behaviors. It is linked to altered neurotransmitter pathways due to enzyme deficiencies. Symptoms may become more evident as social demands increase with age. Daily life is impacted by difficulties in forming relationships, but behavioral therapies can enhance social skills.
Feeding difficulties include problems with sucking, swallowing, or digesting food. These arise from neuromuscular incoordination and gastrointestinal issues. If not addressed, they can lead to poor growth and nutritional deficiencies. Special feeding techniques and nutritional support can help manage these challenges.
Behavioral issues may include aggression, hyperactivity, or anxiety. These are thought to result from neurotransmitter imbalances affecting mood and behavior regulation. Such issues can persist or worsen without intervention, affecting social interactions and learning. Behavioral therapy and medications can help manage these symptoms.
Less Common
Microcephaly is characterized by a smaller than normal head size, indicating reduced brain growth. It results from impaired cell proliferation and energy deficits in the developing brain. This condition is usually apparent at birth or develops in early infancy. It can lead to intellectual disabilities, but supportive care and therapies can help optimize development.
Sleep disturbances include difficulties falling or staying asleep, and irregular sleep patterns. These are linked to disruptions in brain chemistry and circadian rhythms. Persistent sleep issues can exacerbate cognitive and behavioral problems. Sleep hygiene practices and medications can help improve sleep quality.
What Causes Adenylosuccinate lyase deficiency?
Adenylosuccinate lyase deficiency is caused by mutations in the ADSL gene, located on chromosome 22q13.1. The ADSL gene encodes the enzyme adenylosuccinate lyase, which plays a crucial role in the purine nucleotide cycle by catalyzing the conversion of adenylosuccinate to AMP and fumarate. Mutations in the ADSL gene can lead to structural changes in the enzyme, reducing its catalytic activity or stability. This enzymatic deficiency results in the accumulation of succinylpurines, which are toxic to cells. The buildup of these metabolites disrupts cellular energy balance and impairs mitochondrial function. Neighboring cells and tissues, particularly in the brain, are affected due to the high energy demands and reliance on purine metabolism. Neuroinflammation is triggered as the immune system responds to cellular stress and damage. This inflammatory response can exacerbate neuronal injury and contribute to the degeneration of white matter. The pattern of symptoms, including developmental delay and seizures, reflects the regions of the brain most affected by metabolic and inflammatory disturbances. Variability in disease severity among patients can be attributed to the specific nature of the mutations, residual enzyme activity, and genetic or environmental modifiers. Some patients may experience more pronounced neurodevelopmental issues, while others might have milder cognitive impairments. The involvement of the complement system in neuroinflammation further complicates the disease progression. Understanding the precise molecular and cellular disruptions helps in developing targeted therapies. Research continues to explore how these pathways can be modulated to alleviate symptoms and improve outcomes.
How is Adenylosuccinate lyase deficiency Diagnosed?
Typical age of diagnosis: Adenylosuccinate lyase deficiency is typically diagnosed in infancy or early childhood when developmental delays and neurological symptoms become apparent. Diagnosis often occurs after parents notice developmental regression or seizures, prompting medical evaluation.
Clinicians look for developmental delays, seizures, and behavioral abnormalities. A detailed family history is essential to identify any hereditary patterns. Physical examination may reveal hypotonia, microcephaly, or other neurological signs. This step helps narrow down the differential diagnosis to metabolic or genetic disorders.
Magnetic Resonance Imaging (MRI) is the preferred modality. It may show cerebral atrophy, white matter abnormalities, or delayed myelination. These findings support the diagnosis of a metabolic disorder and help exclude structural causes like tumors. Imaging findings guide further metabolic and genetic testing.
Specific tests include plasma amino acids and urine organic acids. Elevated levels of succinylpurines are sought as biomarkers. Abnormal results show increased succinyladenosine and succinylaminoimidazole carboxamide riboside. These results prompt genetic testing for confirmation.
The ADSL gene is sequenced to identify mutations. Both missense and nonsense mutations can be found. Identifying pathogenic mutations confirms the diagnosis of adenylosuccinate lyase deficiency. Results are crucial for genetic counseling and assessing recurrence risk in families.
Adenylosuccinate lyase deficiency Treatment Options
Antiepileptic drugs (AEDs) are used to manage seizures. They work by stabilizing neuronal membranes and reducing excitability. Commonly used AEDs include valproate and levetiracetam. Clinical evidence shows variable efficacy, with some patients achieving seizure control. Side effects may include sedation, liver dysfunction, and behavioral changes.
Techniques include motor skills training and sensory integration therapy. Goals are to improve motor function and enhance sensory processing. Sessions are typically conducted 2-3 times per week for 30-60 minutes. Outcomes are measured by improvements in motor milestones and functional abilities. Long-term benefits include enhanced quality of life and reduced disability.
Surgical intervention is not typically indicated for adenylosuccinate lyase deficiency. The condition is primarily managed through medical and supportive therapies. Focus remains on symptomatic management and supportive care. Surgical risks and post-operative care are not applicable. Multidisciplinary management is emphasized instead.
The team includes neurologists, geneticists, dietitians, and therapists. Interventions focus on symptom management, nutritional support, and developmental therapies. Psychosocial support is provided through counseling and support groups. Family education is crucial for managing expectations and care at home. Long-term monitoring involves regular follow-ups to adjust care plans as needed.
When to See a Doctor for Adenylosuccinate lyase deficiency
- Severe seizures — this is an emergency because it can lead to brain damage or be life-threatening.
- Sudden loss of consciousness — this is critical as it may indicate severe neurological compromise.
- Acute respiratory distress — this requires immediate attention as it can lead to respiratory failure.
- Developmental delays — significant as they may indicate worsening of the condition and require evaluation.
- Frequent vomiting — concerning as it can lead to dehydration and may indicate metabolic imbalance.
- Persistent irritability — significant as it may reflect neurological distress and warrants medical review.
- Mild lethargy — monitor energy levels and ensure adequate hydration and nutrition at home.
- Intermittent headaches — monitor frequency and intensity, and consult a doctor if they worsen.
Adenylosuccinate lyase deficiency — Frequently Asked Questions
Is this condition hereditary?
Adenylosuccinate lyase deficiency is inherited in an autosomal recessive pattern. This means both parents must carry one copy of the mutated gene to pass it to their child. De novo mutations are rare but possible. Carriers typically do not show symptoms but can pass the gene to offspring. Genetic counseling is recommended for affected families to understand risks and options.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly and is influenced by the severity and age of onset. Early diagnosis and management can improve outcomes, though severe cases may result in early mortality. Respiratory complications and severe neurological impairment are common causes of death. Treatment can extend survival and improve quality of life. Families should have realistic expectations and prepare for long-term care needs.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, genetic testing, and metabolic studies. The time from first symptoms to diagnosis can vary, often taking months to years. Neurologists and geneticists are commonly involved in the diagnostic process. Delays often occur due to the rarity and non-specific early symptoms of the condition. Confirmation is usually achieved through genetic testing identifying mutations in the ADSL gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy being a promising area of study. Novel approaches such as enzyme replacement therapy are also under investigation. ClinicalTrials.gov is a valuable resource for finding relevant trials. Patients should discuss potential participation in trials with their healthcare provider. New treatments may take several years before becoming widely available.
How does this condition affect daily life and activities?
Adenylosuccinate lyase deficiency can significantly impact mobility and self-care, often requiring assistive devices. Educational challenges are common, necessitating special education services. Social and emotional difficulties may arise due to developmental delays and communication issues. The condition can place a substantial burden on families, requiring extensive support. Adaptive technologies and community resources can greatly aid in daily management.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Adenylosuccinate lyase deficiency.
Jurecka A, Zikanova M, Kmoch S et al. · J Inherit Metab Dis · 2015 · PMID: 25112391
- 2.Adenylosuccinate lyase deficiency.
Spiegel EK, Colman RF, Patterson D · Mol Genet Metab · 2006 · PMID: 16839792
- 3.Neurologic aspects of adenylosuccinate lyase deficiency.
Ciardo F, Salerno C, Curatolo P · J Child Neurol · 2001 · PMID: 11392513
- 4.Adenylosuccinate lyase deficiency: an update.
Van den Berghe G, Van den Bergh F, Vincent MF et al. · Adv Exp Med Biol · 1994 · PMID: 7660929
- 5.Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in Caenorhabditis elegans.
Moro CA, Sony SA, Franklin LP et al. · PLoS Genet · 2023 · PMID: 37773959
- 6.Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: Long-term follow-up of seven patients from four families and appraisal of the literature.
Cutillo G, Masnada S, Lesca G et al. · Epilepsia Open · 2024 · PMID: 37842880
- 7.Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.
Magnusen AF, Hopkin RJ, Vorhees C et al. · Brain Behav Immun Health · 2025 · PMID: 40896413
- 8.Biochemical and molecular genetic correlation in adenylosuccinate lyase deficiency.
Salerno C, Crifò C · Nucleosides Nucleotides Nucleic Acids · 2004 · PMID: 15571240
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-05